The CEO's sale is a textbook cashless exercise pattern (option exercise + immediate sale to cover taxes and realize gains) following a 364% stock appreciation from the $21.58 strike. At 0.12% of market cap, this cluster is too small to signal fundamental concern. The Q1 earnings beat and $200M rusfertide milestone are the dominant catalysts. Monitor for any secondary offerings or insider sales exceeding 0.5% of market cap in the next 30 days.
Price Chart
Executive Summary
Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director Bryan Giraudo on May 8, creating a two-insider sell cluster totaling $8.11M. The sales occurred just 9 days after a massive Q1 earnings beat (revenue $56.4M vs $16.3M consensus, EPS $0.05 vs -$0.65 consensus) driven by milestone payments from ICOTYDE FDA approval and the rusfertide opt-out. While the earnings beat is clearly positive, the CEO's large open-market sale immediately after exercising options at $21.58/share (realizing ~$7.5M profit) is a routine cashless exercise pattern — the stock is up ~364% from the option strike, and the sale represents only ~0.12% of the $6.7B market cap, falling below the 0.5% materiality threshold.
Key Financial Metrics
Key Facts
- CEO Dinesh Patel sold 75,000 shares at $100.12 for $7.51M on May 12, 2026, after exercising options at $21.58/share
- Director Bryan Giraudo sold 6,000 shares at $100.00 for $600K on May 8, 2026
- Total cluster value: $8.11M, representing ~0.12% of PTGX's $6.7B market cap
- Sales occurred 9 days after Q1 2026 earnings beat: revenue $56.4M vs $16.3M consensus, EPS $0.05 vs -$0.65 consensus
- CEO's option exercises were non-cash (A/F) or at $21.58 strike — the $7.5M sale is a standard cashless exercise pattern, not a bearish signal
- Prior 30-day insider activity showed 4 sells totaling $19.2M, consistent with routine post-vesting diversification
Financial Impact
Total insider sales of $8.11M represent ~0.12% of $6.7B market cap — well below the 0.5% materiality threshold for significant insider selling
Risk Factors
- CEO sold 100% of the exercised shares — no retention signals confidence beyond the option exercise itself
- Stock is up significantly post-earnings; additional insider sales could emerge as lockups expire
- The $200M rusfertide payment is a one-time event — future quarters will need to show recurring revenue from ICOTYDE sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTGX-1778803638393 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 144 | $148.29 $145.09 | ▲ +2.16% | ▲ +1.10% | $140.06 (+5.55%) |
Jun 18, 2026 15w ago | 8-K | $115.03 $140.91 | ▲ +22.50% | ▲ +22.65% | $140.06 (+21.76%) |
Jun 12, 2026 16w ago | Institutional Cluster | $109.78 $131.42 | ▲ +19.71% | ▲ +17.93% | $140.06 (+27.58%) |
May 12, 2026 20w ago | 144 | $103.88 $109.79 | ▼ −5.69% | ▼ −6.30% | $140.06 (−34.83%) |
May 8, 2026 21w ago | Insider Cluster | $99.36 $97.38 | ▼ −1.99% | ▼ −2.02% | $140.06 (+40.96%) |
May 8, 2026 21w ago | Insider Cluster | $99.36 $97.38 | ▼ −1.99% | ▼ −2.02% | $140.06 (+40.96%) |
May 5, 2026 21w ago | 8-K | $103.97 $95.41 | ▼ −8.23% | ▼ −11.01% | $140.06 (+34.71%) |
Feb 25, 2026 31w ago | 8-K | $87.10 $104.31 | ▲ +19.76% | ▲ +25.00% | $140.06 (+60.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access